Management of postoperative microvascular compromise and ischemia reperfusion injury in breast reconstruction using autologous tissue transfer: Retrospective review of 2103 flaps.


Journal

Microsurgery
ISSN: 1098-2752
Titre abrégé: Microsurgery
Pays: United States
ID NLM: 8309230

Informations de publication

Date de publication:
Feb 2022
Historique:
revised: 20 07 2021
received: 19 05 2021
accepted: 22 10 2021
pubmed: 3 12 2021
medline: 4 2 2022
entrez: 2 12 2021
Statut: ppublish

Résumé

Although rates of microvascular thrombosis following free-flap breast reconstruction are low, debate persists about the optimal methods to restore blood flow and prevent ensuing flap shrinkage or fibrosis. Here we evaluate our management of microvascular compromise, including both a review of our approach for restoring blood flow and addressing the ensuing inflammatory changes following ischemia reperfusion. We conducted a retrospective review of autologous free tissue transfer breast reconstructions from 1/2010 to 1/2020. Patients who had flaps requiring take-back for salvage were identified. Management of microvascular compromise and ischemia reperfusion injury were recorded. Of 2103 flaps were used in the breast reconstructions, 47 flaps required take-back for microvascular compromise (2.2%). Most flaps were either completely salvaged (n = 29, 61.7%) or partially salvaged (n = 5, 10.6%). Thirteen (27.7%) were a total flap loss, for an overall rate of 0.8% (including 3 flaps with no salvage attempt). Management of microvascular compromise most often included revision of the anastomosis (n = 33, 70.2%), thrombectomy (n = 27, 57.4%), tissue plasminogen activator administration (n = 26, 55.3%), and vein grafts (n = 18, 38.3%). Management of ischemia reperfusion included intraoperative steroids (n = 33, 70.2%), postoperative steroids (n = 17, 38.6%), and postoperative therapeutic anticoagulation (n = 27, 61.3%). Of 34 salvaged flaps, 5 (14.7%) had partial flap loss and/or fat necrosis on clinical examination at an average follow-up of 2.7 ± 2.8 years. Salvage of microvascular compromise in autologous breast reconstruction should include restoration of blood flow and management of ischemia reperfusion injury. Attention to both is paramount for successful outcomes.

Sections du résumé

BACKGROUND BACKGROUND
Although rates of microvascular thrombosis following free-flap breast reconstruction are low, debate persists about the optimal methods to restore blood flow and prevent ensuing flap shrinkage or fibrosis. Here we evaluate our management of microvascular compromise, including both a review of our approach for restoring blood flow and addressing the ensuing inflammatory changes following ischemia reperfusion.
METHODS METHODS
We conducted a retrospective review of autologous free tissue transfer breast reconstructions from 1/2010 to 1/2020. Patients who had flaps requiring take-back for salvage were identified. Management of microvascular compromise and ischemia reperfusion injury were recorded.
RESULTS RESULTS
Of 2103 flaps were used in the breast reconstructions, 47 flaps required take-back for microvascular compromise (2.2%). Most flaps were either completely salvaged (n = 29, 61.7%) or partially salvaged (n = 5, 10.6%). Thirteen (27.7%) were a total flap loss, for an overall rate of 0.8% (including 3 flaps with no salvage attempt). Management of microvascular compromise most often included revision of the anastomosis (n = 33, 70.2%), thrombectomy (n = 27, 57.4%), tissue plasminogen activator administration (n = 26, 55.3%), and vein grafts (n = 18, 38.3%). Management of ischemia reperfusion included intraoperative steroids (n = 33, 70.2%), postoperative steroids (n = 17, 38.6%), and postoperative therapeutic anticoagulation (n = 27, 61.3%). Of 34 salvaged flaps, 5 (14.7%) had partial flap loss and/or fat necrosis on clinical examination at an average follow-up of 2.7 ± 2.8 years.
CONCLUSIONS CONCLUSIONS
Salvage of microvascular compromise in autologous breast reconstruction should include restoration of blood flow and management of ischemia reperfusion injury. Attention to both is paramount for successful outcomes.

Identifiants

pubmed: 34854501
doi: 10.1002/micr.30845
pmc: PMC8810672
mid: NIHMS1758210
doi:

Substances chimiques

Tissue Plasminogen Activator EC 3.4.21.68

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

109-116

Subventions

Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NIH/NCI Cancer Center Support Grant
ID : P30 CA008748 (Memorial Sloan Kettering Cancer Center's research infrastructure)

Informations de copyright

© 2021 Wiley Periodicals LLC.

Références

PLoS One. 2013 Aug 14;8(8):e71628
pubmed: 23977093
Biomed Res Int. 2016;2016:3758278
pubmed: 27699168
Microvasc Res. 2017 Jul;112:72-78
pubmed: 28347755
Transplantation. 2009 Apr 15;87(7):956-65
pubmed: 19352113
Plast Reconstr Surg. 1982 Jan;69(1):61-7
pubmed: 7031723
Circulation. 1997 Aug 5;96(3):761-8
pubmed: 9264480
Plast Reconstr Surg. 2007 Jul;120(1):187-195
pubmed: 17572562
Plast Reconstr Surg. 2018 Apr;141(4):855-863
pubmed: 29595720
Plast Reconstr Surg. 2012 Sep;130(3):579-589
pubmed: 22929244
Plast Reconstr Surg. 1990 Sep;86(3):492-8; discussion 499-501
pubmed: 2201050
J Reconstr Microsurg. 2016 May;32(4):316-24
pubmed: 26872023
Microsurgery. 2011 Oct;31(7):505-9
pubmed: 21630338
J Plast Reconstr Aesthet Surg. 2015 Jun;68(6):830-6
pubmed: 25812752
J Extra Corpor Technol. 2017 Sep;49(3):192-197
pubmed: 28979043
Anesthesiology. 2007 Nov;107(5):776-84
pubmed: 18073553
J Thorac Cardiovasc Surg. 2009 Dec;138(6):1445-7
pubmed: 19660323
Microsurgery. 2013 Oct;33(7):505-13
pubmed: 23946137
Plast Reconstr Surg. 2007 Jun;119(7):2092-2100
pubmed: 17519706
Plast Reconstr Surg. 2012 Jul;130(1):105-113
pubmed: 22418714
J Plast Reconstr Aesthet Surg. 2009 Feb;62(2):244-9
pubmed: 18499547
J Reconstr Microsurg. 2003 Nov;19(8):523-30
pubmed: 14722839
Transplantation. 2015 Oct;99(10):2118-23
pubmed: 25757215
Am J Surg. 2013 Sep;206(3):410-7
pubmed: 23759697
Plast Reconstr Surg. 2018 Jan;141(1):20e-27e
pubmed: 29280859
Plast Reconstr Surg. 2004 Jan;113(1):277-83
pubmed: 14707647
Anaesthesia. 2014 Jul;69(7):777-84
pubmed: 24773303
J Reconstr Microsurg. 2007 Feb;23(2):69-73
pubmed: 17330201
Plast Reconstr Surg. 2018 Oct;142(4):1025-1034
pubmed: 30020236
J Reconstr Microsurg. 2008 Jul;24(5):305-14
pubmed: 18615389

Auteurs

Michelle Coriddi (M)

Plastic and Reconstructive Surgery Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA.

Paige Myers (P)

Division of Plastic and Reconstructive Surgery, Department of Surgery, University of Michigan, Ann Arbor, Michigan, USA.

Babak Mehrara (B)

Plastic and Reconstructive Surgery Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA.

Jonas Nelson (J)

Plastic and Reconstructive Surgery Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA.

Peter G Cordeiro (PG)

Plastic and Reconstructive Surgery Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA.

Joseph Disa (J)

Plastic and Reconstructive Surgery Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA.

Evan Matros (E)

Plastic and Reconstructive Surgery Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA.

Joseph Dayan (J)

Plastic and Reconstructive Surgery Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA.

Robert Allen (R)

Plastic and Reconstructive Surgery Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA.

Colleen McCarthy (C)

Plastic and Reconstructive Surgery Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH